Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
index medicus (9) 9
oncology (8) 8
lung neoplasms - drug therapy (7) 7
carcinoma, non-small-cell lung - drug therapy (6) 6
middle aged (6) 6
article (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
female (5) 5
male (5) 5
adult (4) 4
aged (4) 4
alk (4) 4
lung cancer (4) 4
lung neoplasms - pathology (4) 4
adenocarcinoma (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
carcinoma, non-small-cell lung - metabolism (3) 3
hematology, oncology and palliative medicine (3) 3
lung neoplasms - genetics (3) 3
neoplasm staging (3) 3
nsclc (3) 3
respiratory system (3) 3
anaplastic lymphoma kinase (2) 2
animals (2) 2
antigens, differentiation, b-lymphocyte - genetics (2) 2
cell lung-cancer (2) 2
crizotinib (2) 2
disease-free survival (2) 2
dosage and administration (2) 2
erlotinib (2) 2
erlotinib hydrochloride (2) 2
gefitinib (2) 2
histocompatibility antigens class ii - genetics (2) 2
lung neoplasms - metabolism (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - therapeutic use (2) 2
pulmonary and respiratory medicine (2) 2
pulmonary/respiratory (2) 2
pyrazoles - administration & dosage (2) 2
pyridines - administration & dosage (2) 2
quinazolines - therapeutic use (2) 2
receptor, epidermal growth factor - antagonists & inhibitors (2) 2
receptor, epidermal growth factor - genetics (2) 2
young adult (2) 2
1st-line chemotherapy (1) 1
acquired-resistance (1) 1
adaptor proteins, signal transducing - genetics (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - pathology (1) 1
adolescent (1) 1
angiogenesis (1) 1
animal structures (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - pharmacokinetics (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
biochemistry & molecular biology (1) 1
biomarkers, tumor - antagonists & inhibitors (1) 1
biomarkers, tumor - metabolism (1) 1
brain (1) 1
brain neoplasms - secondary (1) 1
breast-cancer (1) 1
cancer (1) 1
carboplatin (1) 1
carboplatin - administration & dosage (1) 1
carboplatin - pharmacokinetics (1) 1
carcinoma, non-small-cell lung - diagnosis (1) 1
carcinoma, non-small-cell lung - epidemiology (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - therapy (1) 1
carcinomatosis (1) 1
care and treatment (1) 1
cell biology (1) 1
cell cycle - drug effects (1) 1
cell cycle - genetics (1) 1
cell line, tumor (1) 1
cell proliferation - drug effects (1) 1
cell-lines (1) 1
chemotherapy (1) 1
clinical trial enrollment (1) 1
clinical trials as topic - statistics & numerical data (1) 1
clinical-features (1) 1
clinicaltrials.gov (1) 1
cns metastases (1) 1
cognition disorders - drug therapy (1) 1
cognition disorders - etiology (1) 1
disease (1) 1
dose-response relationship, drug (1) 1
double-blind (1) 1
drug interactions (1) 1
drug therapy (1) 1
drug therapy, combination (1) 1
egfr (1) 1
eml4-alk (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents
by Berge, Eamon M and Doebele, Robert C
Drugs, ISSN 0012-6667, 05/2013, Volume 73, Issue 6, pp. 517 - 517
Metastatic non-small cell lung cancer remains a disease with a high annual incidence and annual mortality worldwide, with limitations in first-line treatment... 
Journal Article
Details down arrow
2. Targeted therapies in non-small cell lung cancer: Emerging oncogene targets following the success of epidermal growth factor receptor
by Berge, Eamon M and Doebele, Robert C
Seminars in Oncology, ISSN 0093-7754, 02/2014, Volume 41, Issue 1, pp. 110 - 125
The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has undergone a paradigm shift since the discovery of sensitizing... 
ANAPLASTIC LYMPHOMA KINASE | KRAS MUTATIONS | K-RAS ONCOGENE | ONCOLOGY | RANDOMIZED PHASE-II | SIGNALING PATHWAY | ACQUIRED-RESISTANCE | GENE AMPLIFICATION | CLINICAL-FEATURES | NEVER-SMOKERS | SOMATIC MUTATIONS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - metabolism | Animals | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Biomarkers, Tumor - metabolism | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Biomarkers, Tumor - antagonists & inhibitors | Molecular Targeted Therapy
Journal Article
Details down arrow
3. Full Text Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
by Vaishnavi, Aria and Capelletti, Marzia and Le, Anh T and Kako, Severine and Butaney, Mohit and Ercan, Dalia and Mahale, Sakshi and Davies, Kurtis D and Aisner, Dara L and Pilling, Amanda B and Berge, Eamon M and Kim, Jhingook and Sasaki, Hidefumi and Park, Seung-Il and Kryukov, Gregory and Garraway, Levi A and Hammerman, Peter S and Haas, Julia and Andrews, Steven W and Lipson, Doron and Stephens, Philip J and Miller, Vince A and Varella-Garcia, Marileila and Jänne, Pasi A and Doebele, Robert C
Nature Medicine, ISSN 1078-8956, 11/2013, Volume 19, Issue 11, pp. 1469 - 1472
We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor... 
RET | ALK | MEDICINE, RESEARCH & EXPERIMENTAL | PROTEIN | ADENOCARCINOMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | KINASE INHIBITORS | CELL-LINES | IDENTIFICATION | GENOME | CELL BIOLOGY | GENE FUSIONS | ROS1 | Antigens, Differentiation, B-Lymphocyte - genetics | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Humans | Receptor, trkA - antagonists & inhibitors | Molecular Sequence Data | In Situ Hybridization, Fluorescence | Oncogene Fusion | Gene Rearrangement | Adaptor Proteins, Signal Transducing - genetics | Cell Line, Tumor | Receptor, trkA - genetics | Protein Kinase Inhibitors - pharmacology | Histocompatibility Antigens Class II - genetics | Crizotinib | Erlotinib | Lung cancer | Genetic aspects | Dosage and administration | Research | Properties | Drug therapy | Gefitinib | Oncogenes | Gene fusion | Cancer | Proteins | Oncology | Phosphorylation | Kinases | Genes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
by Davies, Kurtis D and Le, Anh T and Theodoro, Mariana F and Skokan, Margaret C and Aisner, Dara L and Berge, Eamon M and Terracciano, Luigi M and Cappuzzo, Federico and Incarbone, Matteo and Roncalli, Massimo and Alloisio, Marco and Santoro, Armando and Camidge, D. Ross and Varella-Garcia, Marileila and Doebele, Robert C
Clinical Cancer Research, ISSN 1078-0432, 09/2012, Volume 18, Issue 17, pp. 4570 - 4579
Purpose: Oncogenic gene fusions involving the 3' region of ROS1 kinase have been identified in various human cancers. In this study, we sought to characterize... 
ANAPLASTIC LYMPHOMA KINASE | ALK | SURVIVAL | GLIOBLASTOMA | ONCOLOGY | TYROSINE KINASE | INHIBITOR | Cell Cycle - genetics | Oncogene Proteins, Fusion - metabolism | Protein-Tyrosine Kinases - metabolism | Sodium-Phosphate Cotransporter Proteins, Type IIb - genetics | Humans | Middle Aged | Syndecan-4 - genetics | Male | Sodium-Phosphate Cotransporter Proteins, Type IIb - metabolism | Protein-Tyrosine Kinases - genetics | Adult | Female | Antigens, Differentiation, B-Lymphocyte - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Proto-Oncogene Proteins - genetics | Protein Kinase Inhibitors - administration & dosage | Carcinoma, Non-Small-Cell Lung - therapy | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Aged | Cell Proliferation - drug effects | Histocompatibility Antigens Class II - genetics | Cell Cycle - drug effects | Neoplasm Staging | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents
by Berge, Eamon M and Doebele, Robert C
Drugs, ISSN 0012-6667, 05/2013, Volume 73, Issue 6, pp. 517 - 532
Metastatic non-small cell lung cancer remains a disease with a high annual incidence and annual mortality worldwide, with limitations in first-line treatment... 
PHASE-III TRIAL | PEMETREXED PLUS | SUPPORTIVE CARE | WEEKLY PACLITAXEL | 1ST-LINE CHEMOTHERAPY | PLATINUM-BASED CHEMOTHERAPY | DOUBLE-BLIND | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | GEMCITABINE PLUS CARBOPLATIN | Maintenance Chemotherapy - trends | Lung Neoplasms - drug therapy | Animals | Lung Neoplasms - epidemiology | Maintenance Chemotherapy - methods | Randomized Controlled Trials as Topic - methods | Humans | Carcinoma, Non-Small-Cell Lung - epidemiology | Carcinoma, Non-Small-Cell Lung - diagnosis | Antineoplastic Agents - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung Neoplasms - diagnosis | Index Medicus
Journal Article
Details down arrow
6. Full Text A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry
by McCoach, Caroline E and Berge, Eamon M and Lu, Xian and Barón, Anna E and Camidge, D. Ross
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2016, Volume 11, Issue 3, pp. 407 - 413
Central nervous system (CNS) metastases are common in non small cell lung cancer (NSCLC), yet clinical trials of new drugs in advanced NSCLC have varying... 
CNS metastases | Clinicaltrials.gov | Leptomeningeal disease | Clinical trial enrollment | NSCLC | ALK | PEMBROLIZUMAB | ONCOLOGY | SAFETY | RESPIRATORY SYSTEM | TUMOR BRAIN METASTASES | Carcinoma, Non-Small-Cell Lung - pathology | Clinical Trials as Topic - statistics & numerical data | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Young Adult | Brain Neoplasms - secondary | Neoplasm Metastasis | Adolescent | Adult | Female | Registries | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
by Camidge, D. Ross and Berge, Eamon M and Doebele, Robert C and Ballas, Marc S and Jahan, Thierry and Haigentz, Missak and Hoffman, David and Spicer, James and West, Howard and Lee, Pablo and Yang, Ling and Joshi, Adarsh and Gao, Ling and Yurasov, Sergey and Mita, Alain
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2014, Volume 9, Issue 10, pp. 1532 - 1539
The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel–carboplatin chemotherapy in patients with advanced... 
Carboplatin | Angiogenesis | Ramucirumab | Lung cancer | Paclitaxel | ADENOCARCINOMA | FACTOR RECEPTOR-2 | BREAST-CANCER | ONCOLOGY | RESPIRATORY SYSTEM | MONOCLONAL-ANTIBODIES | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - metabolism | Antibodies, Monoclonal - pharmacokinetics | Carboplatin - administration & dosage | Lung Neoplasms - pathology | Male | Carboplatin - pharmacokinetics | Paclitaxel - pharmacokinetics | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Paclitaxel - administration & dosage | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR
by Berge, Eamon M and Aisner, Dara L and Doebele, Robert C
Journal of Thoracic Oncology, ISSN 1556-0864, 09/2013, Volume 8, Issue 9, pp. e83 - e84
TYROSINE KINASE INHIBITORS | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | ONCOLOGY | RESPIRATORY SYSTEM | Carcinoma, Non-Small-Cell Lung - pathology | Erlotinib Hydrochloride | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Liver Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Liver Neoplasms - drug therapy | Lung Neoplasms - pathology | Mutation - genetics | Adenocarcinoma - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Liver Neoplasms - secondary
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
by Berge, Eamon M and Lu, Xian and Maxson, Delee and Barón, Anna E and Gadgeel, Shirish M and Solomon, Benjamin J and Doebele, Robert C and Varella-Garcia, Maria and Camidge, D. Ross
Clinical Lung Cancer, ISSN 1525-7304, 2013, Volume 14, Issue 6, pp. 636 - 643
Micro-Abstract Retrospective analyses suggest enhanced sensitivity to pemetrexed in crizotinib-naive anaplastic lymphoma kinase-positive (ALK+) non–small-cell... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | ALK | Crizotinib | NSCLC | Pemetrexed | Lung cancer | EML4-ALK | INHIBITION | GENE | ONCOLOGY | CHEMOTHERAPY | LY231514 | Lung Neoplasms - drug therapy | Pyridines - administration & dosage | Guanine - analogs & derivatives | Humans | Middle Aged | Male | Receptor Protein-Tyrosine Kinases - metabolism | Carcinoma, Non-Small-Cell Lung - mortality | Young Adult | Disease-Free Survival | Pyrazoles - administration & dosage | Drug Interactions | Glutamates - administration & dosage | Adult | Female | Aged | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Therapy, Combination | Neoplasm Staging | Guanine - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text EGFR Exon 19 Deletion Mutations and Systemic/Central Nervous System Miliary Metastasis: Clinical Correlations and Response to Therapy
by Poonia, Seerat and Berge, Eamon M and Aisner, Dara L and Damek, Denise and Doebele, Robert C
Clinical Lung Cancer, ISSN 1525-7304, 2014, Volume 15, Issue 5, pp. 387 - 389
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Non–small-cell lung cancer | Erlotinib | Miliary nodules | EGFR | Leptomeningeal | Non-small-cell lung cancer | GEFITINIB | ADENOCARCINOMA | RECHALLENGE | CELL LUNG-CANCER | ONCOLOGY | LEPTOMENINGEAL METASTASES | DISEASE | CARCINOMATOSIS | BRAIN | Carcinoma, Non-Small-Cell Lung - pathology | Erlotinib Hydrochloride | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Sequence Deletion | Carcinoma, Non-Small-Cell Lung - genetics | Exons | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Meningeal Carcinomatosis - pathology | Treatment Outcome | Meningeal Carcinomatosis - secondary | Meningeal Carcinomatosis - genetics | Cognition Disorders - drug therapy | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cognition Disorders - etiology | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Abstract LB-449: KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small-cell lung cancer
by Moran, Diarmuid M and Trusk, Patricia and Shell, Scott A and Camidge, D. Ross and Doebele, Robert C and Berge, Eamon and Vincent, Mark and Bacus, Sarah
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. LB-449 - LB-449
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.